Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) - Concepedia

Concepedia

Publication | Open Access

Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

DOI Full Paper Access

48

Citations

25

References

2022

Year

Benny Johnson, Cara Haymaker, Edwin R. Parra, Luisa M. Solis Soto, Xuemei Wang, Jane V. Thomas, Arvind Dasari, Van K. Morris, Kanwal Raghav, Eduardo Vilar,

Journal for ImmunoTherapy of Cancer

Abstract

NCT03428126.

References

	Year	Citations

Page 1